Publications by authors named "George Prajgrod"
Article Synopsis
- The study focused on understanding the prevalence and clinical implications of Dientamoeba fragilis (DF) and Blastocystis (Bs) in the stool samples of children under 18 years old.
- Out of 36,008 children tested, 32.5% had DF and 7.9% had Bs, but these infections didn't lead to significantly more health issues compared to those with negative results, except for some abdominal pain in DF-positive cases.
- The findings suggest that while DF and Bs are common in children's stool, they likely have limited clinical importance, especially when compared to known pathogenic microorganisms.
Article Synopsis
- - The study aimed to evaluate the clinical significance of Dientamoeba fragilis (DF) and Blastocystis species (Bs) in human stool samples, focusing on their impact on symptoms and clinical outcomes post-testing.
- - An observational analysis of 27,918 patients showed that 22.3% tested positive for DF and 19.2% for Bs, but symptom incidence before testing was similar across groups, and no significant differences in clinical outcomes were found afterward.
- - The findings suggest that positive results for DF or Bs in stool PCR do not correlate with any notable clinical symptoms or treatment responses in patients, indicating limited clinical relevance.
Background: Group B streptococcus (GBS) harbors many virulence factors but there is limited data regarding their importance in colonization in pregnancy and early-onset disease (EOD) in the newborn. We hypothesized that colonization and EOD are associated with different distribution and expression of virulence factors.
Methods: We studied 36 GBS EOD and 234 GBS isolates collected during routine screening.
MRSA in Israel-genomic analysis, prevalence and global perspective.
JAC Antimicrob Resist
August 2022
Background: MRSA is a major global healthcare problem. In 2011, a new variant designated was described, presenting partial identity at the DNA level, thus undetectable by routine PCR.
Objectives: Until now, no reliable information regarding MRSA prevalence was available in Israel.
Background: An Israeli national taskforce performed a multi-center clinical and analytical validation of seven serology assays to determine their utility and limitations for SARS-CoV-2 diagnosis.
Methods: Serology assays from Roche, Abbott, Diasorin, BioMerieux, Beckman-Coulter, Siemens, and an in-house RBD ELISA were included. Negative samples from 2391 individuals representative of the Israeli population, and 698 SARS-CoV-2 PCR positive patients, collected between March and May 2020, were analyzed.